Sanofi swaps top execs with Bayer, triggering a reorganization that puts China in the headlights
Sanofi and Bayer are swapping out two top execs, triggering a reorganization at the French pharma company that will allow for a closer focus on China.
Stefan Oelrich is leaving his job at Sanofi as head of the diabetes and cardio operation, headed back to Bayer as the new chief of its pharma group, where he began his career. Sanofi, meanwhile, recruited Bayer’s Dieter Weinand — who Oelrich is replacing — and assigned him to the office in Bridgewater, NJ, where he’ll run a new primary care unit that combines diabetes/cardio and their “Established Products” group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.